Sinocelltech Group Limited

来自 : 上海证券交易所 发布时间：2021-03-24

Brief Introduction

Sinocelltech Group Limited (\"Sinocelltech\") is a Beijing based innovation-driven biopharmaceutical company, founded by Dr. Xie Liangzhi, an internationally renowned biopharmaceutical expert, in 2002. It is one of the earliest domestic enterprises dedicated to the research and development of biologic drugs. Sinocelltech has been devoting to the development of biopharmaceutical products in a variety of therapeutic and preventive areas, comprising of malignant tumors, autoimmune diseases, infectious diseases and genetic diseases.

Read more...

Sinocelltech has established high-efficiency and high-throughput technology platforms for all stages of R D and manufacturing of biologic drugs, and has independently developed a diversified and distinctive biopharmaceutical product pipeline including monoclonal antibodies, recombinant proteins, and vaccines. Sinocelltech is committed to the mission of providing high-quality and low-cost therapeutic options for Chinese and global patients, meeting the growing medical needs domestically and abroad, and establishing a leading brand in the biopharmaceutical field.

Company Overview Full name Sinocelltech Group Limited Abbreviations Sinocelltech Code 688520 Founded April 23, 2007 Listing June 22, 2020 Domicile Beijing Website www.sinocelltech.com Email ir@sinocelltech.com STAR Theme Biomedicine CSRCSector Pharmaceutical Manufacturing Has weighted voting rights structure? None FinancialsHighlights 2019 2018 2017 Earnings Per Share -2.09 - - R D expenditure as a % of operating revenue 195.65% 147.60% 31.57% Operating Revenue 2.64 2.95 5.99 Net Income -798.12 -459.53 -145.87 Income Statement (Unit: RMB mn) 2019 2018 2017 Operating Revenue 2.64 2.95 5.99 Operating Costs 1.87 0.54 2.20 Operating Income -797.87 -459.56 -145.07 Pretax Income -798.12 -459.53 -145.87 Income Tax - - - Net Income -798.12 -459.53 -145.87 Balance Sheet(Unit: RMB mn) 2019 2018 2017 Assets Current Assets-Total 232.69 83.28 127.81 Non-current Assets-Total 575.50 456.48 359.13 Total Assets 808.19 539.76 486.94 Liabilities Current Liabilities-Total 204.65 228.94 80.55 Non-current Liabilities-Total 568.73 334.66 238.55 Total Liabilities 773.39 563.60 319.10 Stockholder\'s Equity Share Capital 1,468.40 529.93 274.48 Retained Profits -1,432.10 -552.29 -99.03 Minority Interests -1.49 -1.48 -7.61 Total Owners\' Equity 34.80 -23.84 167.84 Cash Flow Statement (Unit: RMB mn) 2019 2018 2017 Net Cash Flows-Operating -485.10 -88.02 -93.28 Net Cash Flows-Investing -72.03 -96.48 -91.62 Net Cash Flows-Financing 714.03 130.46 203.69 Top 10 Shareholders Name No. of Shares Held (mn) % of Shares Held 拉萨爱力克投资咨询有限公司 267.83 69.51% 天津神州安元企业管理咨询合伙企业（有限合伙） 21.90 5.68% 拉萨良昊园投资咨询有限公司 20.00 5.19% 谢良志 16.67 4.33% 宁波梅山保税港区鼎晖孚冉股权投资合伙企业（有限合伙） 11.91 3.09% 宁波清松稳胜企业管理合伙企业（有限合伙） 8.93 2.32% 天津神州安恒企业管理咨询合伙企业（有限合伙） 7.30 1.89% QM65 LIMITED 5.79 1.50% 上海集桑医疗科技有限公司 4.47 1.16% 苏州工业园区启华二期投资中心（有限合伙） 3.86 1.00% 31 Dec 2019